BR112015026023A2 - derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 - Google Patents

derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1

Info

Publication number
BR112015026023A2
BR112015026023A2 BR112015026023A BR112015026023A BR112015026023A2 BR 112015026023 A2 BR112015026023 A2 BR 112015026023A2 BR 112015026023 A BR112015026023 A BR 112015026023A BR 112015026023 A BR112015026023 A BR 112015026023A BR 112015026023 A2 BR112015026023 A2 BR 112015026023A2
Authority
BR
Brazil
Prior art keywords
wee
inhibitors
aminopyrido
pyrimidin
derivatives
Prior art date
Application number
BR112015026023A
Other languages
English (en)
Inventor
John Wilkinson Andrew
roderick o'dowd Colin
Burkamp Frank
Samuel Shane Rountree James
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of BR112015026023A2 publication Critical patent/BR112015026023A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo da patente de invenção para: “derivados de 2-aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1”. a presente invenção se refere a compostos de fórmula (i) que são usados como inibidores da atividade de quinase wee-1. a presente invenção também se refere a composições farmacêuticas que compreendem estes compostos e a métodos de utilização destes compostos no tratamento de câncer e métodos de tratamento de câncer.
BR112015026023A 2013-04-11 2014-04-11 derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 BR112015026023A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1306610.5A GB201306610D0 (en) 2013-04-11 2013-04-11 Pharmaceutical compounds
PCT/GB2014/051136 WO2014167347A1 (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Publications (1)

Publication Number Publication Date
BR112015026023A2 true BR112015026023A2 (pt) 2017-07-25

Family

ID=48537110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026023A BR112015026023A2 (pt) 2013-04-11 2014-04-11 derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1

Country Status (16)

Country Link
US (1) US9714244B2 (pt)
EP (1) EP2984090B1 (pt)
JP (1) JP6412920B2 (pt)
KR (1) KR102250668B1 (pt)
CN (1) CN105209463B (pt)
AU (1) AU2014252828B2 (pt)
BR (1) BR112015026023A2 (pt)
CA (1) CA2909365C (pt)
GB (1) GB201306610D0 (pt)
HK (1) HK1219474A1 (pt)
IL (1) IL242000B (pt)
MX (1) MX362215B (pt)
RU (1) RU2656342C2 (pt)
SG (1) SG11201508405QA (pt)
WO (1) WO2014167347A1 (pt)
ZA (1) ZA201507874B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9718821B2 (en) * 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2016204429A1 (ko) * 2015-06-18 2016-12-22 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물.
KR101845931B1 (ko) * 2015-06-18 2018-04-05 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CN110678169A (zh) 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
EP3652174A4 (en) * 2017-07-13 2021-06-30 Syros Pharmaceuticals, Inc. TAM KINASE INHIBITORS
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3712150A4 (en) 2017-11-01 2021-03-10 Shijiazhuang Sagacity New Drug Development Co., Ltd. MACROCYCLIC COMPOUND SERVING AS AN INHIBITOR OF WEE1 AND ITS APPLICATIONS
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
WO2020083404A1 (zh) 2018-10-26 2020-04-30 南京明德新药研发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
KR20200100429A (ko) * 2019-02-18 2020-08-26 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
KR20210141659A (ko) 2019-03-22 2021-11-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
KR20210150476A (ko) 2019-04-09 2021-12-10 누베이션 바이오 인크. 헤테로시클릭 화합물 및 그의 용도
SG11202111315XA (en) 2019-04-30 2021-11-29 Shijiazhuang Sagacity New Drug Development Co Ltd Crystal form of wee1 inhibitor compound and use thereof
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
IL309037A (en) * 2021-06-04 2024-02-01 Aprea Therapeutics Inc Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2330909B1 (en) * 2008-08-12 2013-09-18 GlaxoSmithKline LLC Chemical compounds
AU2009319051A1 (en) * 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitors for therapeutic treatment
CA2745970A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
AU2009325400A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
CA2841629A1 (en) * 2011-07-15 2013-01-24 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) * 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9718821B2 (en) * 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Also Published As

Publication number Publication date
CA2909365C (en) 2021-11-09
NZ713114A (en) 2021-01-29
RU2015148189A (ru) 2017-05-23
JP2016516763A (ja) 2016-06-09
CN105209463A (zh) 2015-12-30
CA2909365A1 (en) 2014-10-16
US9714244B2 (en) 2017-07-25
JP6412920B2 (ja) 2018-10-24
CN105209463B (zh) 2017-10-13
EP2984090A1 (en) 2016-02-17
HK1219474A1 (zh) 2017-04-07
IL242000B (en) 2021-03-25
MX2015014234A (es) 2016-06-16
AU2014252828A1 (en) 2015-11-05
WO2014167347A1 (en) 2014-10-16
US20160060258A1 (en) 2016-03-03
KR20150143668A (ko) 2015-12-23
AU2014252828B2 (en) 2018-07-05
EP2984090B1 (en) 2017-05-31
ZA201507874B (en) 2017-09-27
MX362215B (es) 2019-01-09
GB201306610D0 (en) 2013-05-29
SG11201508405QA (en) 2015-11-27
KR102250668B1 (ko) 2021-05-10
RU2656342C2 (ru) 2018-06-05

Similar Documents

Publication Publication Date Title
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CO2017011851A2 (es) Compuestos novedosos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112016007396A2 (pt) derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos
DOP2015000170A (es) Compuestos químicos
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
EA201600434A1 (ru) Применение производных бензимидазолпролина
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]